{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:17Z","timestamp":1794047477443,"version":"4.8.0"},"reference-count":33,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Hydroxyurea (HU) is frequently used in the early phase of chronic myeloid leukemia (CML) to achieve cytoreduction prior to tyrosine kinase inhibitor therapy. However, its impact on CML stem and progenitor cells (SPC) remains largely unknown. This study utilized targeted proteo-transcriptomic expression data on 596 genes and 51 surface proteins in 60,000 CD14-CD34+ cells from chronic phase CML patients to determine effects of short-term HU treatment (4-19 days) on CML SPC. Peripheral blood and bone marrow samples were obtained from 17 CML patients eligible for short-term HU treatment (3 patients before and after HU, 7 patients before HU and 7 patients after HU) and subjected to single-cell CITE-sequencing and\/or flow cytometry analysis. The analysis revealed enhanced frequencies of hemoglobin-expressing (HBA1, HBA2, HBB) erythroid progenitor cells in blood and bone marrow following HU treatment. In addition, there was an accumulation of cell subsets with S\/G2\/M phase-related gene and protein expression, likely representing cells arrested in, or progressing slowly through, the cell cycle. The increased frequency of cells in S\/G2\/M phase after HU was observed already among the most immature leukemic stem cells (LSC), and patients with a large fraction of LSC in the S\/G2\/M phase showed poor responsiveness to tyrosine kinase inhibitor treatment. We conclude that short-term HU treatment entails differentiation of erythroid progenitor cells and alters the characteristics of LSC in CML. The results imply that studies of LSC and progenitor populations in CML should take effects of initial HU therapy into account.<\/jats:p>","DOI":"10.3324\/haematol.2024.285071","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T18:08:42Z","timestamp":1723658922000},"page":"117-128","source":"Crossref","is-referenced-by-count":5,"title":["Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia"],"prefix":"10.3324","volume":"110","author":[{"given":"Hana","family":"Komic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin S.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovisa","family":"Wennstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tagore Sanketh","family":"Bandaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Jaako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Hellstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik B.","family":"Thor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Martner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"70903","unstructured":"Hungerford DA. Chromosome studies in human leukemia. 1. Acute leukemia in children. J Natl Cancer Inst. 1961; 27:983-1011."},{"key":"70904","doi-asserted-by":"crossref","unstructured":"Quint\u00e1s-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006; 81(7):973-988.","DOI":"10.4065\/81.7.973"},{"key":"70905","doi-asserted-by":"crossref","unstructured":"Cortes JE, Saglio G, Kantarjian HM. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016; 34(20):2333-2340.","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"70906","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Saglio G, Hughes TP. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; 30(5):1044-1054.","DOI":"10.1038\/leu.2016.5"},{"key":"70907","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Heimpel H, Hasford J. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994; 84(12):4064-4077.","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064"},{"key":"70908","doi-asserted-by":"crossref","unstructured":"Wolfe HR, Rein LAM. The evolving landscape of frontline therapy in chronic phase chronic myeloid leukemia (CML). Curr Hematol Malig Rep. 2021; 16(5):448-454.","DOI":"10.1007\/s11899-021-00655-z"},{"key":"70909","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"70910","doi-asserted-by":"crossref","unstructured":"Kockerols CCB, Geelen I, Levin MD. The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era. Haematologica. 2022; 107(8):1940-1943.","DOI":"10.3324\/haematol.2021.280501"},{"key":"70911","doi-asserted-by":"crossref","unstructured":"Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukemia. Cancer. 1972; 29(4):1052-1056.","DOI":"10.1002\/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7"},{"key":"70912","doi-asserted-by":"crossref","unstructured":"Cokic VP, Smith RD, Beleslin-Cokic BB. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003; 111(2):231-239.","DOI":"10.1172\/JCI200316672"},{"key":"70913","doi-asserted-by":"crossref","unstructured":"Lou TF, Singh M, Mackie A, Li W, Pace BS. Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gammaglobin gene activation. Exp Biol Med. 2009; 234(11):1374-1382.","DOI":"10.3181\/0811-RM-339"},{"key":"70914","doi-asserted-by":"crossref","unstructured":"Suboti\u010dki T, Mitrovi\u0107 Ajti\u0107 O, Djiki\u0107 D. Nitric oxide mediation in hydroxyurea and nitric oxide metabolites\u2019 inhibition of erythroid progenitor growth. Biomolecules. 2021; 11(11):1562.","DOI":"10.3390\/biom11111562"},{"key":"70915","doi-asserted-by":"crossref","unstructured":"Ikuta T, Sellak H, Odo N, Adekile AD, Gaensler KML. Nitric oxidecGMP Signaling stimulates erythropoiesis through multiple lineage-specific transcription factors: clinical implications and a novel target for erythropoiesis. PLoS One. 2016; 11(1):e0144561.","DOI":"10.1371\/journal.pone.0144561"},{"key":"70916","doi-asserted-by":"crossref","unstructured":"H\u00fcmmer J, Kraus S, Br\u00e4ndle K, Lee-Thedieck C. Nitric oxide in the control of the in vitro proliferation and differentiation of human hematopoietic stem and progenitor cells. Front Cell Dev Biol. 2020; 8:610369.","DOI":"10.3389\/fcell.2020.610369"},{"key":"70917","doi-asserted-by":"crossref","unstructured":"Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999; 94(6):2056-2064.","DOI":"10.1182\/blood.V94.6.2056.418k13_2056_2064"},{"key":"70918","doi-asserted-by":"crossref","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020; 20(3):158-173.","DOI":"10.1038\/s41568-019-0230-9"},{"key":"70919","doi-asserted-by":"crossref","unstructured":"Houshmand M, Simonetti G, Circosta P. Chronic myeloid leukemia stem cells. Leukemia. 2019; 33(7):1543-1556.","DOI":"10.1038\/s41375-019-0490-0"},{"key":"70920","doi-asserted-by":"crossref","unstructured":"Mojtahedi H, Yazdanpanah N, Rezaei N. Chronic myeloid leukemia stem cells: targeting therapeutic implications. Stem Cell Res Ther. 2021; 12(1):603.","DOI":"10.1186\/s13287-021-02659-1"},{"key":"70921","doi-asserted-by":"crossref","unstructured":"Nilsson MS, Komic H, Gustafsson J. Multiomic single-cell analysis identifies von Willebrand factor and TIM3-expressing BCR-ABL1+ CML stem cells. bioRxiv. 2023.","DOI":"10.1182\/blood-2023-184992"},{"key":"70922","doi-asserted-by":"crossref","unstructured":"Hao Y, Hao S, Andersen-Nissen E. Integrated analysis of multimodal single-cell data. Cell. 2021; 184(13):3573-3587.","DOI":"10.1016\/j.cell.2021.04.048"},{"key":"70923","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez L, Caballero N, Fern\u00e1ndez-Calleja L, Karkoulia E, Strouboulis J. Regulation of GATA1 levels in erythropoiesis. IUBMB Life. 2020; 72(1):89-105.","DOI":"10.1002\/iub.2192"},{"key":"70924","doi-asserted-by":"crossref","unstructured":"Buscemi G, Carlessi L, Zannini L. DNA damage-induced cell cycle regulation and function of novel Chk2 phosphoresidues. Mol Cell Biol. 2006; 26(21):7832-7845.","DOI":"10.1128\/MCB.00534-06"},{"key":"70925","doi-asserted-by":"crossref","unstructured":"Warfvinge R, Geironson L, Sommarin MNE. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017; 129(17):2384-2394.","DOI":"10.1182\/blood-2016-07-728873"},{"key":"70926","doi-asserted-by":"crossref","unstructured":"Cortes J, Quint\u00e1s-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011; 117(6):1113-1122.","DOI":"10.1002\/cncr.25527"},{"key":"70927","doi-asserted-by":"crossref","unstructured":"Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012; 120(7):1390-1397.","DOI":"10.1182\/blood-2012-03-378919"},{"key":"70928","unstructured":"Gui CY, Jiang C, Qian RL. [The role of hydroxyurea in globin gene expression and cell differentiation of human erythroleukemia cell line]. Shi Yan Sheng Wu Xue Bao. 1997; 30(4):375-382."},{"key":"70929","doi-asserted-by":"crossref","unstructured":"Krishnan V, Schmidt F, Nawaz Z. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood. 2023; 141(22):2738-2755.","DOI":"10.1182\/blood.2022017295"},{"key":"70930","doi-asserted-by":"crossref","unstructured":"Kapor S, Vukoti\u0107 M, Suboti\u010dki T. Hydroxyurea induces bone marrow mesenchymal stromal cells senescence and modifies cell functionality in vitro. J Pers Med. 2021; 11(11):1048.","DOI":"10.3390\/jpm11111048"},{"key":"70931","doi-asserted-by":"crossref","unstructured":"Apraiz A, Mitxelena J, Zubiaga A. Studying cell cycle-regulated gene expression by two complementary cell synchronization protocols. J Vis Exp. 2017; 124:55745.","DOI":"10.3791\/55745"},{"key":"70932","doi-asserted-by":"crossref","unstructured":"Behbehani GK, Samusik N, Bjornson ZB, Fantl WJ, Medeiros BC, Nolan GP. Mass cytometric functional profiling of acute myeloid leukemia defines cell-cycle and immunophenotypic properties that correlate with known responses to therapy. Cancer Discov. 2015; 5(9):988-1003.","DOI":"10.1158\/2159-8290.CD-15-0298"},{"key":"70933","doi-asserted-by":"crossref","unstructured":"Rinaldi I, Reksodiputro AH, Jusman SW. Longer hydroxyurea administration prior to imatinib mesylate is risk factor for unsuccessful major molecular response in chronicphase chronic myeloid leukemia: possibility of P-glycoprotein role. Asian Pac J Cancer Prev. 2019; 20(12):3689-3695.","DOI":"10.31557\/APJCP.2019.20.12.3689"},{"key":"70934","doi-asserted-by":"crossref","unstructured":"Lange T, Niederwieser C, Gil A. No advantage of imatinib in combination with hydroxyurea over imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML Study Group. Leuk Lymphoma. 2020; 61(12):2821-2830.","DOI":"10.1080\/10428194.2020.1786556"},{"key":"70935","doi-asserted-by":"crossref","unstructured":"Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000; 96(9):3195-3199.","DOI":"10.1182\/blood.V96.9.3195"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285071\/77470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285071\/77944","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11726\/77470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:10Z","timestamp":1794046030000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285071","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}